An observational study in Cataract, sponsored by Taipei Nobel Eye Clinic. Completed at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Taipei Nobel Eye Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Cataract with a site in Taiwan — 2 open to participants now, 2 under way, none of them phase 3. Cataract · Taiwan.
Among the 15 studies in Cataract with a site in Taiwan, this one is one of 3 that started in 2022, is one of 6 observational ones, and was the 11th registered.
1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.
Browse Cataract studies →2 of the 15 studies in Cataract with a site in Taiwan are open now. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 18+ · Healthy volunteers
National Taiwan University Hospital · Sites in Taiwan
Ages 18–80
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is close to the median of 90 across 477 observational studies indexed under Cataract.
Median enrollment 60 across the 9 interventional studies, 111 across the 6 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 15 have an industry lead sponsor. The 6 most frequent:
Taipei Nobel Eye Clinic is the lead sponsor of 5 studies on the registry; none are open to participants now.
Taipei Nobel Eye Clinic has 2 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
1 of the studies in Cataract with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07693829National Taiwan University HospitalA Study on the Application of Smart Bed-Exit Alert Assistive Devices for Detecting Preoperative Bed Exits in Ophthalmic Surgery Patients in the Operating Room | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Cataract with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of study is to evaluate the quality of vision after bilateral Vivity or Vivity toric EDOF IOLs implantation in Taiwan.
This study was a prospective, single arm study. The inclusion criteria for this study were the presence of cataracts in both eyes and corrected distance visual acuity (CDVA) of both eyes under 20/40, who received bilateral Vivity IOL implantation after cataract surgery, targeting emmetropia or mini-monovision of both eyes. Phacoemulsification cataract surgery was performed on all patients. The exclusion criteria were complicated cataract; corneal opacities or irregularities; severe dry eye (Schirmer's test I ≤ 5 mm); amblyopia; anisometropia; surgical complications such as posterior capsular bag rupture, vitreous loss, or IOL tilt/decentration; coexisting ocular pathologies such as glaucoma, nondilating pupil, history of intraocular surgery, refractive surgery, or retinopathy; optic nerve or macular diseases; and refusal or inability to maintain follow-up. When corneal astigmatism was more than 0.75 diopters (D), a toric IOL was implanted.
Patients who intended for sequential bilateral cataract surgery and implanted with Vivity/Vivity IOL would be asked to include in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Visual acuity (LogMAR)
Uncorrected binocular far, intermediate and near visual acuity. Corrected binocular far, intermediate and near visual acuity.
Time frame: From enrollment to the end of treatment at 3 months
Intermediate reading speed (seconds)
The intermediate reading speed was measured by IReST - International Reading Speed Texts Chinese Edition
Time frame: From enrollment to the end of treatment at 3 months
Plan to share: No
Ran from Dec 2022 to primary completion in Oct 2024, 21 months.
Of 169 non-industry observational studies under Cataract, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 30. This study's 21 months is above that.
Counting every sponsor, half of 236 studies reached it within 16 months; a quarter within 9 and three quarters within 30.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Dec 2024 → Oct 2024 and completion Dec 2024 → Nov 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taipei Nobel Eye Clinic